{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:49:47Z","timestamp":1776055787884,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Satralizumab, a monoclonal antibody targeting the interleukin\u20106 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real\u2010world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified patients diagnosed with NMOSD in the TriNetX federated health research platform between January 2018 and April 2024. This international platform was accessed via Taipei Medical University. Patients were followed for 1\u2009month to 3\u2009years. A 1:1 propensity\u2010score matching (PSM) analysis balanced baseline characteristics between the satralizumab and conventional immunosuppressant groups. Risk ratios (RRs) were calculated for relapse risk and safety outcomes, including sepsis, respiratory infection, urinary tract infection, anemia, neutropenia, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 220 patients received satralizumab, while 1744 received conventional immunosuppressants. After PSM, 218 patients remained in each group. Satralizumab was associated with a significantly lower relapse risk at 1\u2009month (RR: 0.38, 95% CI 0.21\u20130.66), 3\u2009months (RR: 0.43, 95% CI 0.28\u20130.66), 6\u2009months (RR: 0.50, 95% CI 0.33\u20130.70), 9\u2009months (RR: 0.62, 95% CI 0.46\u20130.83), 12\u2009months (RR: 0.63, 95% CI 0.47\u20130.83), 24\u2009months (RR: 0.60, 95% CI 0.42\u20130.86) and 36\u2009months (RR: 0.52, 95% CI 0.32\u20130.83). Across all follow\u2010up intervals, numbers needed to treat were consistently between 4 and 9. No significant differences were observed in infection rates, anemia, neutropenia, or mortality between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Satralizumab demonstrated superior efficacy in reducing NMOSD relapse rates compared to conventional immunosuppressants while maintaining a comparable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acn3.70246","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:21:56Z","timestamp":1763130116000},"page":"665-675","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease"],"prefix":"10.1002","volume":"13","author":[{"given":"Li\u2010Tsung","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Chang Gung Memorial Hospital, Linkou Medical Center  Taoyuan Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui\u2010An","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine School of Medicine, College of Medicine, Taipei Medical University  Taipei Taiwan"},{"name":"Department of Emergency Medicine Taipei Medical University Hospital  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0470-2184","authenticated-orcid":false,"given":"Sheng\u2010Feng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Taipei Medical University Hospital  Taipei Taiwan"},{"name":"Department of Public Health, School of Medicine College of Medicine, Taipei Medical University  Taipei Taiwan"},{"name":"School of Public Health College of Public Health, Taipei Medical University  Taipei Taiwan"},{"name":"Department of Evidence\u2010Based Center Taipei Medical University Hospital  Taipei Taiwan"},{"name":"Department of Medical Research Taipei Medical University Hospital  Taipei Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-015-0387-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-2-169"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000403"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.143529"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1099376"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12733"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510379247"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1516126"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1310\/GTFR-2DRX-M6YE-ELXR"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83760-2"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1214\/09-STS313"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2024.0485"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53838-y"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.01.008"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0240-9"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.20.11981"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000110"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24208"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.141"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106176"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4666"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5314541"},{"issue":"2","key":"e_1_2_10_30_1","article-title":"Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin\u20106 Receptor","volume":"16","author":"Meher B. R.","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-00995-9"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106444"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00640-7"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105683"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102334"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106384"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acn3.70246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.70246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:16:54Z","timestamp":1776053814000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.70246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/acn3.70246"],"URL":"https:\/\/doi.org\/10.1002\/acn3.70246","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"2025-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}